Aziyo, Sientra team up to expand distribution of SimpliDerm
fotostorm
- Aziyo Biologics (NASDAQ:AZYO) signed an agreement granting Sientra certain non-exclusive rights in the U.S. to sell and distribute SimpliDerm for select use in reconstruction surgery.
- "This agreement is intended to help drive meaningful revenue growth and support our strategy of quickly and profitably expanding the reach of our proprietary biologics platforms," said Aziyo President and CEO Randy Mills.
- Mills added that the partnership will help expand women's access to biologic solutions for successful reconstruction procedures.
- Aziyo noted that SimpliDerm is to be used for repairing or replacing damaged or insufficient integumental tissue or for other homologous uses of human integument.